Vmbook Online ordering

Drug Delivery

Delcath Systems, Inc. (DCTH) is a clinical stage specialty pharmaceutical company focused on oncology. The company is developing a proprietary drug delivery system for the treatment of primary and metastatic liver cancers. The company's drug delivery system, called the Delcath Hepatic Delivery System, is designed to deliver high concentrations of ultra-high potency anti-cancer drugs directly to the liver while reducing systemic exposure.

As of the time of this writing, Delcath Systems, Inc. is not a publicly traded company. The company's stock was delisted from the Nasdaq Stock Market in November 2019 and is no longer trading on any U.S. stock exchange.

Prior to delisting, the company's financials showed significant losses over the past several years. For the year ended December 31, 2018, the company reported a net loss of $14.7 million, compared to a net loss of $12.9 million for the year ended December 31, 2017. As of December 31, 2018, the company had an accumulated deficit of $331.9 million.

It is important to note that the company's financials and stock price prior to delisting may not be indicative of future performance. Additionally, the company's focus on liver cancer and its proprietary drug delivery system may present unique opportunities and challenges.

I would recommend consulting with a financial advisor or conducting further research before making investment decisions related to Delcath Systems, Inc. or any other company. Additionally, it's always good to check the latest and up-to-date information, since my knowledge is based on the data I have and it might be not the most recent one.